Science Corp. raised $230 million to develop and launch the PRIMA wireless retinal implant on the US market[1][2]. PRIMA is intended for patients with geographic atrophy (GA) caused by age-related macular degeneration (AMD), which affects more than 5 million people worldwide[1][2]. A clinical study published in the New England Journal of Medicine showed that the implant restores functional central vision; 80% of patients achieved a significant improvement in visual acuity and were able to read letters, numbers and words[1][2]. The 2 x 2 mm x 30 µm implant acts as an array of artificial photoreceptors that stimulate the remaining retinal cells to transmit signals to the brain[1][2][3]. No significant decrease in existing peripheral vision was observed and 95% of serious adverse events resolved within 2 months after implantation[1][2]. The company has filed for regulatory approval in Europe and is awaiting a decision from the FDA in the US[1][2][7]. PRIMA is based on technology developed by Professor Daniel Palanker at Stanford University[1][2].